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http://dx.doi.org/10.1016/j.ajic.2015.06.001Efforts to reduce health careeassociated infections (HAIs) have grown in both scale and sophistication
over the past few decades; however, the increasing threat of antimicrobial resistance and the impact of
new legislation regarding HAIs on health care economics make the ﬁght against them all the more ur-
gent. On-demand polymerase chain reaction (PCR) technology has proven to be a highly effective
weapon in this ﬁght, offering the ability to accurately and efﬁciently identify disease-causing pathogens
such that targeted and directed therapy can be initiated at the point of care. As a result, on-demand PCR
technology has far-reaching inﬂuences on HAI rates, health care outcomes, hospital length of stay,
isolation days, patient satisfaction, antibiotic stewardship, and health care economics. The basics of on-
demand PCR technology and its potential to impact health care have not been widely incorporated into
health care education and enrichment programs for many of those involved in infection control and
prevention, however. This article serves as a primer on on-demand PCR technology and its ramiﬁcations.
Copyright  2015 by the Association for Professionals in Infection Control and Epidemiology, Inc.
Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Health careeassociated infections (HAIs) continue to be one of The ability to rapidly identify the pathogens causing HAIs has
the most critical burdens on the nation’s health care system, rep-
resenting a signiﬁcant source of patient morbidity and mortality. A
multistate point-prevalence study of 183 acute care hospitals in the
United States reported an estimated 648,000 inpatients with
721,800 HAIs during 2011.1 Although efforts to reduce the incidence
of HAIs have grown in both scale and sophistication, thanks in part
to multidisciplinary collaboration in the medical community, ad-
vances in technology, and implementation of and mandates for
evidence-based HAI-speciﬁc safe practices, the battle against HAIs
is far from over.son, MD, 1321 Seahawk Lane,
n).
fessionals in Infection Control and
enses/by-nc-nd/4.0/).been an integral part of this battle. The development of polymerase
chain reaction (PCR) testing of blood, sputum, urine, and stool
specimens has been a critical step forward in this effort to increase
the rapidity, sensitivity, and speciﬁcity of pathogen diagnosis. First
developed in the 1980s, PCR is a method for amplifying speciﬁc
sequences of DNA, which can, among other things, aid in the
diagnosis of diseases and the identiﬁcation of bacteria and viruses.2
Although batch PCR testing has been available for several decades
for diagnostic purposes, on-demand PCR testing with results
obtainable at the point of care andwithin 2 hours is a relatively new
advancement that, unfortunately, has not yet been widely incor-
porated into the education and enrichment programs for many
involved in infection control and prevention.
A recent survey of more than 200 infection preventionists (IPs)
from across the country, of whom 75 responded, identiﬁed signif-
icant knowledge gaps among IPs with regard to PCR technology3:Epidemiology, Inc. Published by Elsevier Inc. This is an open access article under the
M. Spencer et al. / American Journal of Infection Control 43 (2015) 1102-8 1103 Only 8% reported having PCR testing available at point of care in
any department (eg on the inpatient nursing ward or in the
intensive care unit [ICU] as opposed to in the microbiology
laboratory).
 69% reported having PCR testing available to all health care
departments in their facility.
 41% reported not understanding how PCR technology works.
 59% reported using rapid PCR for screening in addition to
diagnosis and treatment.
 Only 41% reported being involved in their facility’s purchase
decision of PCR equipment.
 Only 7% reported having performed studies on PCR and its
beneﬁt to their IP program.
 When IPs were asked to name the organisms for which PCR
testing does not yet exist but for which testing would be most
helpful, carbapenem-resistant Enterobacteriaceae was
mentioned most often. Of note, every other response indicated
an organism for which rapid PCR testing is already available.
 57% of the IPs’ facilities that did not have access to PCR tech-
nology had no plans to obtain it in the near future.
 30% of the IPs did not know the brand of PCR equipment used
in their facility (S. Barnes, personal communication, June 7,
2014).
Given the critical need for accurate and expedient diagnosis of
infection in today’s health care settings, it is imperative that those
professionals at the forefront of the ﬁght against HAIs understand
the basics of PCR technology along with its potential impact on HAI
rates, antimicrobial stewardship, patient isolation, and health care
economics.
ON-DEMAND PCR TESTING
PCR testing of patient specimens involves harnessing the ability
of the enzyme DNA polymerase to synthesize new DNA strands
complementary to a template strand when exposed to short pieces
of single-stranded DNA. These short pieces, called primers, are
designed to be compatible with the template strand. In the detec-
tion of bacteria and viruses by PCR, speciﬁc primers, chosen based
on the known gene sequences of particular bacterial and viral DNA,
are added to the tested samples and will allow DNA polymerase to
amplify numerous copies of the pathogen’s DNA if it is present.
In the early days of PCR testing, blood, sputum, urine, or stool
samples were collected and run in batches in centralized locations.
Although this PCR testing offered more expedient and, in some
cases, more sensitive and speciﬁc results than other testing mo-
dalities, there remained some drawbacks. These included the need
for highly skilled laboratory staff to run the tests (some states
permit only licensed medical technologists or licensed pro-
fessionals to run them), high vigilance for contamination given the
exquisite sensitivity of PCR, and the time involved in collecting
samples, bringing them to a centralized location, and running them
at set times of the day or when an optimal number of samples are
received. These factors have been made obsolete by the advent of
on-demand PCR testing, however.
The on-demand PCR technology does not require specialized
training for health care staff and allows for testing of patients at the
point of care in numerous settingsdemergency departments (EDs),
satellite clinics, and ICUs, among othersdwith turnaround times of
approximately 2 hours or less. Health care personnel are able to run
the test samples in fully integrated and automated PCR testing units
that can be placed in the setting of choice. Currently, on-demand
PCR testing is available for methicillin-resistant Staphylococcus
aureus (MRSA), methicillin-sensitive S aureus, Clostridium difﬁcile,
Mycobacterium tuberculosis (MTB), Chlamydia trachomatis, Neisseriagonorrhoeae, vancomycin-resistant enterococcus, enteroviral men-
ingitis, norovirus, and group B Streptococcus.
The question then becomes how does on-demand PCR testing
impact health care delivery? The answer is that the impact is far-
reaching: inﬂuencing HAI rates, health care outcomes, hospital
length of stay (LOS), isolation days, patient satisfaction, antibiotic
stewardship, and health care economics.
IMPACT OF ON-DEMAND PCR TESTING
HAI rates
Rapid and reliable identiﬁcation of pathogens, particularly those
that pose the most signiﬁcant risks to patients, is an integral part of
reducing HAI rates. As Sue Barnes, National Leader for Infection
Prevention for Kaiser Permanente, says, “the critical ﬁrst step in
preventing transmission of communicable diseases in health care
settings, such as CDI [Clostridium difﬁcile infection], MRSA,
pertussis, and TB [tuberculosis] is prompt diagnosis. This guides
expedient isolation of the patient and PPE [personal protective
equipment] use as indicated, as well as prompt treatment to
minimize and optimize antibiotic use and reduce transmission
risk.”
In their 2008 Annals of Internal Medicine article, Robicsek et al
reported implementing on-demand PCR testing followed by isola-
tion and decolonization of patients who tested positive for MRSA.
They subsequently saw a “reduction by more than half of health
careeassociated MRSA disease occurring during admission and in
the 30 days after discharge”.4 Similar results have been seen in
other institutions that switched to on-demand PCR testing for
MRSA. Loyola University Medical Center reported a 68% reduction
in MRSA infections,5 and New England Baptist Hospital reported a
60% reduction.6 After implementing an active MRSA high-risk pa-
tient screening program using on-demand PCR testing, J.T. Mather
Hospital reported an 84% reduction in MRSA cases, an 84% cost
reduction, and a decrease in average LOS in their ICUs and cardiac
care units from 4.4 to 3.3 days between 2008 and 2014.7 The Albert
Einstein Health Care Network reported a 27% reduction in MRSA
rates after initiating its Stop MRSA Acquisition and Spread in our
Hospital campaign involving on-demand PCR testing and new
clinical protocols.8
Awad et al reported an overall decrease in health caree
associated MRSA infections from 2 to 1 per 1000 bed-days and a
statistically signiﬁcant overall decrease in surgical site infections
(SSIs) at the Michael E. Debakey Veterans Affairs Medical Center
when universal on-demand PCR screening for MRSA (results
obtainable within 70 minutes) was implemented, along with con-
tact precautions for infected or colonized patients, improved hand
hygiene, a “cultural transformation campaign with staff and lead-
ership,” and “ongoing monitoring of process and outcome mea-
sures”.9 This 5-pronged approach, referred to as the “MRSA
bundle,” was later implemented across the Veterans Affairs health
care system, resulting in a 62.2% decrease in health careeassociated
ICU MRSA infections and a 44.7% decrease in non-ICU health
careeassociated MRSA infections, as reported by Jain et al in their
2011 study.10 One study examining CDI incidence noted a decrease
in health care onsete, health care facilityeassociated CDI rates from
52% to 16% in the 6 months after they implemented PCR testing
instead of enzyme immunoassay testing (EIA).11
Antimicrobial stewardship
Prudent administration of antibiotics has become an issue at the
forefront of the ﬁght against HAIs in this era of multidrug-resistant
organisms. The State of California has actually mandated that all
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the judicious use of antibiotics” with a “quality improvement
committee” responsible for oversight.12 On-demand PCR testing
represents a key opportunity to enhance antimicrobial steward-
ship. Studies have shown that more expedient receipt of bacterial
identiﬁcation and antimicrobial susceptibility results has a signiﬁ-
cant impact on physicians’ administration of antimicrobials.13,14
Trenholme et al demonstrated that the receipt of “rapid” results
(within approximately 8 hours) had a statistically signiﬁcant in-
ﬂuence on antibiotic use, with more effective and less expensive
therapy initiated compared with when results were obtained at
48 hours.13 This is particularly relevant in the ambulatory care
setting, where the opportunity to initiate optimal therapy is critical
given the uncertainty of follow-up care. If a patient presents with
an infected wound and the offending organism is identiﬁed within
2 hours, then the health care provider can initiate precise, targeted
therapy, thereby avoiding the need for broader-spectrum
antimicrobials. Patient satisfaction and compliance are likely to
increase as patients leave armed with the knowledge that they are
receiving ideal therapy. As Dr Jorge Parada, Medical Director of the
Infection Control Program at Loyola University Medical Center,
stated, “on-demand PCR testing allows for a switch from empiric
therapy to directed therapy, which might be a game changer in
the emergency department (J. Parada, personal communcation,
June 7, 2014).”
Pulia et al studied the use of on-demand PCR testing for MRSA
in patients presenting to the ED with soft tissue abscesses
and found that the observed ideal antibiotic selection rates
improved by 45% in the PCR-tested group compared with the
nonePCR-tested group.15 In addition, they were able to obtain
results within 80 minutes, with no impact on LOS in the ED in the
PCR group.15
Although rapid pathogen identiﬁcation is inarguably the critical
ﬁrst step in optimizing antimicrobial therapeutic choices, assessing
antimicrobial susceptibilities is clearly an integral part of deter-
mining ideal treatment. Obtaining results from traditional suscep-
tibility testing involving phenoptypic methods often takes days,
increasing the time during which patients might be placed un-
necessarily on broad-spectrum antibiotics or jeopardizing those
patients receiving an antibiotic to which their infecting pathogen is
resistant (M. Spencer, personal communication, June 7, 2014).16,17
Rapid molecular antibiotic susceptibility testing (RAMAST), in
which positive blood cultures are diluted and incubated with and
without antibiotics and then subjected to quantitative on-demand
PCR testing to examine for the presence or absence of growth, of-
fers great potential for expediting the determination of antibiotic
susceptibilities and promoting antimicrobial stewardship.17,18 In
the case of MTB disease, multiple studies have shown that
on-demand PCR testing for MTB and rifampin (MTB/RIF) resistance
is highly sensitive and speciﬁc, which, as the World Health
Organization stated, allows for “early and appropriate treatment
initiation, as well as accelerating the implementation of MDR-TB
[multidrug-resistant TB] control measures and ultimately
reducing TB case incidence.”19-21 In fact, in 2010 the World Health
Organization endorsed on-demand PCR testing for MTB/RIF and
initiated a 3-year rollout of the technology in 2013 to 21 countries,
primarily in Africa, Asia, and South America.22
Isolation
The practice of implementing transmission-based precautions
for patients with known infectious agents has become a mainstay
of modern health care delivery. The Centers for Disease Control and
Prevention has issued recommendations for isolating patients with
a variety of different infectious agents, including active CDI andactive MRSA infection, as well as those patients with a history of
previous MRSA infection/colonization or CDI.23 A study published
in 2013 from a California hospital documented that over a 1-year
period, 18.1% of hospital days were isolation days, and that MRSA
and CDI were responsible for 75.5% of all hospital isolation days in
the hospital.24 Before the availability of on-demand PCR testing, if a
patient’s MRSA status, for example, was not known, then
isolation and contact precautions often were not initiated
until culture or batch PCR testing results could be obtained.
Depending on the testing modality used, receiving those results
could take as many as several days. On-demand PCR testing, when
implemented as part of a preadmission screening process, allows
for the rapid diagnosis of a patient’s MRSA status so that the
necessary isolation precautions can be instituted at the beginning
of hospitalization, thereby preventing any potential exposures from
the onset.
Although isolating patients with highly infectious pathogens is
a very effective infection prevention and control approach, it is a
cumbersome practice for patients, practitioners, and health care
facilities.25 Hospital rooms must be allocated for isolation patients,
and practitioners and visitors must don PPE, such as gowns, masks,
and gloves. Many infection prevention and control programs
require a series of negative cultures to remove patients from
isolation, and thus patients must wait days, sometimes evenweeks,
to receive laboratory results. Furthermore, the practice of imple-
menting isolation precautions for a history of multidrug-resistant
organisms and rule-out TB cases can adversely affect emergency
room throughput, because the patient must wait in the ED for a
private room that might not be ready until in-house discharges are
complete.
Studies have shown that with increasing numbers of patients in
contact isolation, health care worker (HCW) compliance with these
precautions tends to decline.25 In a 9-month prospective cohort
study conducted at 11 teaching hospitals, Dhar et al recorded an
overall rate of compliance with contact precautions of just 28.9%
and found that when the burden of isolation (ie, proportion of
patients in contact isolation precautions) reached 40%, compliance
rates began to decrease.25 The ability to obtain rapid results
could help alleviate this problem. As Maureen Spencer, Corporate
Infection Prevention Consultant at Universal Health Services,
said, “If you can determine positive or negative results in a
predictably effective time frame, you will increase human
compliance and vigilance. Velocity and predictability drive patient
workﬂow.”
On-demand PCR testing brings the potential to dramatically
reduce both the number of patients placed in isolation and the
number of days isolated patients must remain under precautions.
In their 2009-2010 study, Catanzaro and Cirone demonstrated a
signiﬁcant decrease in isolation days, tests ordered, and metroni-
dazole treatment in patients screened for CDI with PCR compared
with those screened with EIA. In fact, they noted a decrease in the
incidence of health careeassociated CDIs from 4.4 per 10,000
patient-days to 0.9 per 10,000 patient-days when PCR testing was
used.11
Novak-Weekley et al compared the sensitivities and speciﬁcities
of 2 different testing algorithms as well as on-demand PCR and
found the following results: glutamate deydrogenase (GDH)-EIA,
sensitivity 55.6%, speciﬁcity 98.3%; GDH-EIA-cell culture cytotoxin
neutralization (CCCN), sensitivity 83%, speciﬁcity 96.7%;
on-demand PCR, sensitivity 95.1%, speciﬁcity 99.4%.26 At a time
when as many as 13 in every 1000 in-patients have CDI and
approximately 109,000 patients die annually from CDI, these
differences are noteworthy.11
Shenoy et al conducted a randomized controlled trial comparing
the impact of passive and active screening with culture and PCR for
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demonstrated a 55% reduction in patient-days on contact
precautions with active PCR screening, with an estimated annual
savings of $1,539,180.27 They noted that a single PCR assay
compared with 3 cultures had a sensitivity of 93.9% and speciﬁcity
of 92.0%, and found that, “with regard to averted CP [contact
precaution] days and their associated costs.the most substantial
impact is appreciated when active screening using single PCR is
implemented”.27
Having the ability to obtain highly sensitive and speciﬁc diag-
nostic results either at the time of admission or before admission
not only can shorten the isolation period, but also can prevent
unnecessary isolations.
Health care economics
Reducing unnecessary isolation days has far greater implica-
tions than simply increasing HCW compliance and patient satis-
faction, just as reducing HAI rates and improving antimicrobial
stewardship have ramiﬁcations beyond improving patient
outcomes. All of these factors carry signiﬁcant economic
consequences. Even in the preeon-demand PCR era, studies have
shown that the ability to obtain more expedient pathogen
identiﬁcation has signiﬁcant cost-saving consequences.14,28
HAI costs
The direct annual hospital cost of treating HAIs has been re-
ported to range from $28.4 billion to as high as $45 billion,
depending on whether the ﬁgures are adjusted for the consumer
price index for all urban consumers or for inpatient hospital
services.29 Although these total numbers are staggering, it is
important to look at the impact of drug-resistant organisms and
difﬁcult-to- treat organisms like CDI on these costs. Zimlichman
et al conducted a meta-analysis of the literature covering a 27-year
period to assess the ﬁnancial impact of HAIs on the US health care
system and reported average costs (in 2012 $US) of $20,785 for a
non-MRSA SSI and $42,300 for a MRSA SSI.30 Similarly, another
study found an average cost of $45,814 for a non-MRSA central
lineeassociated bloodstream infection (CLABSI), compared with
$58,614 for a MRSA CLABSI.30 In a retrospective analysis of the New
York state Department of Health data from 2007-2008, Lipp et al
estimated an annual cost of health careeassociated CDI of $55
million.31
Numerous studies have performed costebeneﬁt analyses of
screening patients for resistant pathogens like MRSA. Nyman et al
studied the cost of screening ICU patients with standard culture,
chromogenic agar, and PCR and imposing contact precautions on
those colonized with MRSA compared with no intervention.31 They
noted that for all 3 testing modalities, “when the cost of the
intervention is netted against the cost reduction from reduced
MRSA infection treatment costs, screening of ICU patients produces
a net cost savings to the hospital”.32 Hubben et al studied the costs
and effects of selective and universal hospital admission screening
for MRSA using a simulation model and found that in high MRSA-
prevalence settings, selective screening with PCR was the most
cost-saving strategy, particularly when the cost of single room
isolation was factored in.33 In fact, they estimated a net beneﬁt of
averted MRSA infection when using selective PCR screening of
$28.7 million over a 15-year period for the 3-hospital health care
system model in their study.33 In their 2005-2007 randomized,
double-blind, placebo-controlled study conducted at 5 hospitals in
The Netherlands, Bode et al demonstrated a signiﬁcant reduction in
the risk of SSIs caused by S aureus in patients screened with on-
demand PCR and then decolonized with mupirocin nasalointment and chlorhexidine gluconate soap.34 This screening and
decolonization also was associated with a reduction in the mean
hospital LOS of almost 2 days.34 The debate over universal versus
targeted MRSA screening is ongoing and beyond the scope of this
article, but omission of screening may be associated with
risk.32,33,35
Similar trends have been seen with the use of on-demand PCR
testing for MTB.36 In 2013, Millman et al performed a costebeneﬁt
analysis of on-demand PCR testing compared with smear micro-
scopy for MTB.36 They reported a 48% reduction in total annual
isolation bed use and an average savings of $2278 per admission
with the use of on-demand PCR versus smear microscopy.36 The
authors noted that a number of intangible cost savings, such as
“decreased risk of health careeassociated complications while
hospitalized because of decreased time in the hospital.and faster
return towork and family,” could potentially add additional savings
for both health care facilities and individual patients.36
Ultimately, when a decision is made regarding adopting new
technology, particularly when it requires budgetary changes, a
hospital’s or health care system’s corporate leaders must be on
board with the decision. It thus becomes imperative to look at the
ﬁnancial impact of averted HAIs from the hospital administration
perspective. Shepard et al did this in a retrospective study pub-
lished in JAMA Surgery in 2013.37 They examined data from a 3-year
period at 4 Johns Hopkins Health System acute care hospitals and
reported some very noteworthy ﬁndings, including a total increase
in proﬁts for the health system of $2,268,589 if all SSIs were
eliminated and $12,164,457 if 30-day readmissions were not
reimbursed.37 They noted that patient with an SSI had on average
signiﬁcantly longer LOS compared with patients without an SSI
(10.56 vs 5.64 days), as well as a signiﬁcantly higher 30-day read-
mission rate (51.94 vs 8.19 readmissions per 100 procedures).37
They also found a signiﬁcantly higher total cost for patients with
an SSI compared with those without an SSI but, interestingly, lower
daily costs for patients with an SSI.37 They posited that a patient
with an SSI occupying a room for an extended period represents a
lost opportunity for hospital revenue, given the fact that at least 1, if
not more, patients without an SSI patients with shorter LOS but
higher daily charges could be housed in that room.37
Reimbursement
An added dimension to these costs is how HAI rates and read-
mission rates drive hospital performance and thus reimbursement.
Several programs implemented by the Centers for Medicaid and
Medicare Services stand to have a signiﬁcant impact on hospital
ﬁnances. In 2008, the Present on Admission policy began to restrict
payment for certain secondary diagnoses that were not present on
admission and are considered preventable.38 With institution of
the value-based purchasing program in 2010, hospitals began to see
their health care outcomes linked to payment by receiving greater
reimbursement for better health care outcomes and lower reim-
bursement for inferior outcomes. The more recent Hospital-
Acquired Condition (HAC) Reduction Program will penalize the
quartile of hospitals with the highest HAC rates by 1% of their
inpatient Medicare revenue. The qualifying HAC conditions are a
composite of a number of patient safety indicators (PSI-90), along
with catheter-associated urinary tract infections and CLABSIs.39
These conditions will expand to include 2 SSIs (colon surgery and
abdominal hysterectomy) in ﬁscal year 2016 and then MRSA and
CDI in ﬁscal year 2017.39 With all 3 programs operating at 100% by
2017, a hospital could face a worst-case scenario of losing 6% of its
inpatient Medicare reimbursement.40 Health care facilities are
essentially being called to task for the fact that evidence suggests as
many as 70% of HAIs are preventable.41
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reduce their outbreak insurance policy costs. Health care in-
stitutions insure themselves against the numerous consequences
associated with an infectious disease outbreakdbusiness inter-
ruption costs, patient relocation costs, and cleanup costs among
them. It is well known that the insurance industry’s goal is to
reduce their risk exposure. A facility with access to the most ac-
curate and rapid diagnostic capabilities certainly stands to mitigate
that risk exposure and potentially lead to outbreak policy
reductions.Implications
The evidence supporting the potential for on-demand PCR
testing to signiﬁcantly impact HAI rates, health care delivery, and
hospital economics is strong, yetdas our IP survey indicatesdbasic
knowledge of on-demand PCR technology and its impact appears to
be suboptimal among a critical group of health care workers. Filling
these knowledge gaps will require an emphasis on education,
communication, collaboration, and standardization in the medical
community at large:
 Education. Infectious disease physician directors and IPs need
to partner with laboratory scientists to educate hospital exec-
utives about the savings and revenue opportunities associated
with on-demand PCR testing. Similarly, larger organizations,
such as APIC, need to partner with laboratory organizations,
such as the American Society for Clinical Laboratory Scientists,
to provide educational support to regional and local chapters
and smaller institutions that might not have access to or
familiarity with on-demand PCR.
 Communication. It is commonly felt that physicians often have
the best success in persuading a health care facility’s C-suite
leaders to adopt new technology. As such, physicians involved
with antibiotic stewardship programs and infection prevention
and control need to be educated on the economics of on-
demand PCR testing so that they are better equipped to
communicate not just the health care beneﬁts, but also the
ﬁnancial beneﬁts to these leaders. Similarly, IPs also must be
educated on the economics if they are to successfully
communicate with C-suite executives.
 Collaboration. Institutions must take a multidisciplinary
approach to on-demand PCR testing. Departments such as In-
fectious Diseases, Microbiology/Laboratory, Infection Preven-
tion and Control, Nursing, Surgical Services, Anesthesiology,
and Ancillary Services need to collaborate both in their efforts
to obtain access to on-demand PCR testing and in the consid-
eration of sharing the budget burden and return on investment.
These departments need to work together to develop a busi-
ness plan demonstrating the return on investment to present
to C-suite executives.
 Standardization. Facilities using on-demand PCR testing must
establish evidence-based guidelines for integrating PCR
testing. Process improvement teams should be established
during the implementation of on-demand PCR testing to study
cost avoidance, cost savings, improved workﬂow, increased
throughput, and other outcome measures in an effort to sup-
port the increased budgetary impact in the microbiology
laboratory.
As the medical community continues to battle HAIs and adapt to
the changing landscape of health care reimbursement and eco-
nomics, taking advantage of new technology with proven health
care outcome and economic beneﬁts is imperative. As BenjaminFranklin so aptly stated, “By failing to prepare, you are preparing to
fail.”
GLOSSARY OF TERMS
PCR
PCR is a biomedical technology in which multiple copies of a
segment of DNA can be produced. The technique involves the use of
2 short DNA sequences called primers, which are designed to bind
to the beginning and end of a targeted DNA segment. The targeted
DNA segment, the primers, free nucleotides, and the enzyme DNA
polymerase are combined and placed into a PCR machine. The
mixture is initially heated to denature and separate the double-
stranded DNA into single strands. This is followed by cooling,
which facilitates binding of the primers to the single DNA strands.
DNA polymerase then synthesizes new strands of DNA from the
single-stranded templates beginning with the primers, resulting in
a double-stranded DNA molecule consisting of 1 old DNA strand
and 1 new DNA strand. Each new DNA molecule can serve as a
template for repetitions of this cycle, such that millions of copies
can be produced.
Batch PCR
Batch PCR refers to the processing of a group or batch of
collected samples intended for PCR testing. Different samples are
collected over a set period and processed collectively at a set time
during, typically after an optimal number of samples are received.
Depending on the time of collection and the time of the batch PCR
processing, receipt of results can take multiple hours to days.
On-demand PCR
On-demand PCR testing refers to the ability to process samples
for PCR testing at any location and at any time. Samples can be run
individually as soon as they are collected. Results are available in
less than 2 hours, and there is no need to amass a group of samples
before testing can be initiated. The rapid turnaround time enables
expeditious initiation of results-driven patient management
strategies.
RAMAST
In RAMAST, a 2-step process for assessing the antibiotic sus-
ceptibility of a positive blood culture, the blood culture is diluted
and incubated with and without antibiotics and then subjected to
rapid PCR testing to detect the presence or absence of growth.
Susceptibility results can be available within as few as 9 hours from
when the culture is identiﬁed as positive.
EIA
EIA is a group of techniques that use an enzyme linked to an
antibody or antigen as a marker for the detection of a speciﬁc
molecule of interest (the analyte), which is often a protein. The
antibody or antigen attached to the enzyme is designed speciﬁcally
to bind to the analyte and not to any other substance in the sample.
EIA can be used to detect the presence of bacteria or viruses in body
ﬂuid samples; for example, they are used to detect the presence or
absence of C difﬁcile toxins A and B. Results are typically available
within 24 hours; however, given EIA’s high speciﬁcity but lower
sensitivity, it is not considered diagnostic on its own. EIA is often
used in combination with testing for GDH.
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GDH is an enzyme produced by C difﬁcile as well as many other
bacteria. As a result, testing for the presence of GDH must be
combined with a C difﬁcile toxin A and B assay, given the high
sensitivity but low speciﬁcity of GDH testing alone.
C difﬁcile culture
C difﬁcile is cultured by placing an enteric sample in either a
blood-enriched cycloserine-cefoxitin-fructose agar or a
taurocholate-cycloserine-cefoxitin-fructose agar under anaerobic
conditions, which allows for the isolation of C difﬁcile colonies from
other enteric microorganisms. It is considered to have relatively
high sensitivity but lower speciﬁcity, because asymptomatic
patients (ie, those not considered to have CDI) may carry both the
toxigenic and nontoxigenic strains. Turnaround time for results is
typically 48-96 hours.
CCCN
The CCCN assay was developed as a means of identifying C
difﬁcile toxin B. A dilute fecal eluate is added to a monolayer of
mammalian or human cells. In the presence of C difﬁcile toxin B, the
mammalian cells will round up and slough off the monolayer. If
antitoxin is then added, this phenomenon or effect is reversed,
thereby conﬁrming the presence of C difﬁcile toxin B. The CCCN
assay requires relatively sophisticated laboratory expertise and
resources, including the ability to maintain cell lines for the cyto-
toxicity assay. Turnaround time for results ranges from 24 to
72 hours.
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